INTRODUCTION TP53 (tumor protein P53), a tumor suppressor gene, is the most commonly
mutated cancer-driver gene. Nevertheless, drugs that target mutant p53, the protein product …

Abstract p53 is one of the most well-studied tumor suppressors. It is mutated or deleted in
half of all cancers. In the other half carrying wild type p53, the p53 signaling pathway is …

Half of all human cancers contain TP53 mutations, and in many other cancers, the function
of the p53 protein is compromised. The diversity of these mutations and phenotypes …

Adoptive cell therapy (ACT) with tumor-specific T cells can mediate cancer regression. The
main target of tumor-specific T cells are neoantigens arising from mutations in self-proteins …

TP53 is the most frequently mutated gene across all cancer types. Our understanding of its
functions has evolved since its discovery four decades ago. Initially thought to be an …

Mutations in the TP53 tumour suppressor gene are very frequent in cancer, and attempts to
restore the functionality of p53 in tumours as a therapeutic strategy began decades ago …

The tumor suppressor p53 is lost or mutated in approximately half of human cancers. Mutant
p53 not only loses its anti-tumor transcriptional activity, but also often acquires oncogenic …

Evidence generated over the past 20 years has unequivocally shown that the p53 tumor
suppressor is the most frequently altered gene in human tumors, with more than 25,000 …

It is only recently that drugs targeting K-RAS and Tp53 missense mutations have been
developed, and along with the allele specific nature of some of these drugs comes the …

Mutations of the p53 gene are the most frequently observed genetic changes in human
cancers; often leading to an overexpression of the wild‐type (wt) p53 protein. Demonstrable …